Therapeutic Innovation

Therapeutic Innovation

Would it surprise you to know that we bring innovation to the field of generic medicine? Or that our research and development group includes more than 3,300 scientists and regulatory experts who innovate worldwide every day?

It’s true. And it’s why we’ve challenged ourselves to reach higher and go farther for more than 50 years.

The Science of Solutions

Today we design bioequivalent versions of brand name medicines, many of which are difficult-to-manufacture and difficult-to-formulate. We strive to create enhanced versions of medicines to differentiate our products from the pack. And we pursue innovations in oral solid dose medicines, transdermals, injectables, creams, ointments, antiretrovirals and nearly a dozen other critical areas.

Why? Because we believe every disease can have a treatment. We believe every epidemic should come to an end. Medical conditions great and small should be manageable.

  • Oncology

    From treatments for solid tumors and cancers of the blood to supportive care, Mylan helps healthcare professionals provide their patients with a wide variety of treatments for every stage of cancer survivorship.  Learn more about Mylan's commitment to oncology.
  • Allergy Drugs

    Anaphylaxis

    Anaphylaxis, a life-threatening allergic reaction, is a significant public health problem. When anaphylaxis occurs, every minute matters and immediate access to epinephrine and emergency medical care is crucial. We advocate for increased anaphylaxis awareness, preparedness and access to treatment, because even one anaphylactic episode without access to epinephrine is one too many.

  • Antiretroviral Drugs

    Antiretrovirals

    These medicines treat HIV/AIDS. Often, treatment regimens require a patient to take three or more medicines and may include an ARV medicine that breaks down if not refrigerated. Many places hardest hit by the epidemic are in warm climates—Africa and India, for instance—where refrigeration can be scarce. For such regions, Mylan was able to make a heat-stable version of an ARV medicine that doesn’t require refrigeration.

  • Cardiovascular Drugs

    Cardiovascular

    Our commitment to cardiovascular medicine beats strongly. Using our transdermal technology we have formulated adhesive patches that deliver medicine through the skin.

  • Respiratory Drugs

    Respiratory

    We’re developing asthma and chronic obstructive pulmonary disease (COPD) treatments that use a dry-powder drug-delivery platform technology. Find out more about our other brand name respiratory products.
  • Skin Creams

    Dermatology

    While we manufacture products in many formats—from tablets and capsules to injectables and transdermals—we also produce creams and ointments for dermatology. Our commitment to these medicines gained strength during the 1990s, when we acquired Bertek Pharmaceuticals. Today, we have several products in clinical trials awaiting approval as well as many creams, ointments, sprays and dressings.

  • CNS Drugs

    Central Nervous System

    Mylan products are the second-most dispensed in the neurologic category. These are difficult-to-manufacture and difficult-to-formulate products that treat serious diseases. Our innovation in this category has made us a leader in this area.

Always Moving Forward

Innovation is a part of who we are and the reason we see the opportunity in every challenge.

Research and development

Creating Positive Change

We’re committed to setting new standards in health care for people living with HIV/AIDS.

Taking Action

About 37 million people are currently living with HIV/AIDS.